celastrol has been researched along with Edema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, J; Li, Y; Lin, D; Qiu, Y; Ren, J; Yang, L; Zhu, C | 1 |
| Jun, JG; Kim, DH; Kim, JK; Kim, YH; Lee, BW; Park, JH; Shin, EK | 1 |
2 other study(ies) available for celastrol and Edema
| Article | Year |
|---|---|
Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2.
Topics: Analgesics; Animals; Camphanes; Carrageenan; Disease Models, Animal; Edema; Hyperalgesia; Interleukin-1beta; Interleukin-6; Mice; Mice, Inbred C57BL; Neuralgia; Pentacyclic Triterpenes; Pyrazoles; Receptor, Cannabinoid, CB2; Signal Transduction; Spinal Cord Injuries; Tripterygium; Triterpenes; Tumor Necrosis Factor-alpha | 2014 |
Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii.
Topics: Animals; Complementary Therapies; Edema; Immunohistochemistry; Indolequinones; Inflammation Mediators; Macrophages; Mice; NF-kappa B; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Pentacyclic Triterpenes; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP2 Subtype; Triterpenes | 2009 |